FLKS - フレックス・ファ―マ (Flex Pharma Inc.) フレックス・ファ―マ

 FLKSのチャート


 FLKSの企業情報

symbol FLKS
会社名 Flex Pharma Inc (フレックス・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Flex Pharma Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps muscle cramps and spasms associated with severe neuromuscular conditions and exercise associated muscle cramps (EAMCs). The Company''s product candidates activate certain receptors in primary sensory neurons which then act through neuronal circuits to reduce the repetitive firing or hyperexcitability of alpha-motor neurons in the spinal cord thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps muscle cramps spasms and spasticity associated with severe neuromuscular conditions and exercise-associated muscle cramps segment. The Company''s lead drug product candidate is FLX-787 which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.   フレックス・ファ―マは開発段階の米国のバイオテクノロジ―企業。重度の神経筋に伴う夜間性の下肢痙攣治療薬の開発を手掛ける。筋痙攣とは不意に骨格筋が痛みを伴う痙攣を起こすもので、痛みが数日間続く事がある。現在米国では認可されている夜間性下肢痙攣治療薬が無い為に、同社は新薬、並びに数時間の鎮痛効果のある栄養補助食品を開発中。   Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. The company was founded by Rod MacKinnon, Bruce Bean, Christoph Westphal, Rich Aldrich, Michelle Dipp, and Jennifer M. Cermak in February 2014 and is headquartered in Boston, MA.
本社所在地 800 Boylston Street 24th Floor Boston MA 02199 USA
代表者氏名 Christoph H. Westphal Christoph H. Westphal
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-874-1821
設立年月日 41671
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 22人
url www.flex-pharma.com
nasdaq_url https://www.nasdaq.com/symbol/flks
adr_tso
EBITDA EBITDA(百万ドル) -33.69347
終値(lastsale) 0.4725
時価総額(marketcap) 8537827.41
時価総額 時価総額(百万ドル) 10.51644
売上高 売上高(百万ドル) 1.12051
企業価値(EV) 企業価値(EV)(百万ドル) -5.24053
当期純利益 当期純利益(百万ドル) -34.63574
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Flex Pharma Inc revenues decreased 27% to $424K. Net loss increased 1% to $17.3M. Revenues reflect Other revenue decrease of 10% to $6K. Higher net loss reflects Drug Development segment loss increase of 39% to $10.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.00 to -$0.96.

 FLKSのテクニカル分析


 FLKSのニュース

   Flex Pharma reports Q1 results  2019/05/01 11:53:27 Seeking Alpha
   Flex Pharma files for $100M mixed shelf; shares down 13% after hours  2019/04/24 20:46:59 Seeking Alpha
   Biotechs lead broad market advance, XBI up 5%  2019/01/04 18:11:19 Seeking Alpha
   Biotechs lead broad market advance, XBI up 5%  2019/01/04 18:11:19 Seeking Alpha
   Flex Pharma up 44% on merger with Salarius Pharmaceuticals  2019/01/04 13:05:11 Seeking Alpha
   Flex Pharma reports Q1 results  2019/05/01 11:53:27 Seeking Alpha
   Flex Pharma files for $100M mixed shelf; shares down 13% after hours  2019/04/24 20:46:59 Seeking Alpha
   Biotechs lead broad market advance, XBI up 5%  2019/01/04 18:11:19 Seeking Alpha
   Biotechs lead broad market advance, XBI up 5%  2019/01/04 18:11:19 Seeking Alpha
   Flex Pharma up 44% on merger with Salarius Pharmaceuticals  2019/01/04 13:05:11 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 フレックス・ファ―マ FLKS Flex Pharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)